logo-loader
viewQ BioMed Inc.

Full interview: Q BioMed successfully synthesizes molecule to treat liver cancer in a 'tremendously exciting achievement'

Q BioMed Inc (OTCQB:QBIO) CEO Denis Corin tells Proactive that the New York-based biotech, together with India-based research organization Chemveda Life Sciences, has made a breakthrough with its therapy as a potential chemotherapy to treat liver cancer.

Corin says the molecule called Uttroside-B, is in pre-clinical development, and the company looks forward to submit it as an investigational new drug in 1Q of 2020.

Quick facts: Q BioMed Inc.

Price: 2.99 USD

OTCMKTS:QBIO
Market: OTCQB
Market Cap: $50 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Q BioMed Inc. named herein, including the promotion by the Company of Q BioMed Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Q BioMed boss says 'all systems go' to prep for...

Q BioMed Inc (OTCMKTS:QBIO) CEO Denis Corin tells Proactive since announcing that the FDA has cleared its contract manufacturer IsoTherapeutics Group LLC to produce the company’s non-opioid cancer bone pain drug Strontium-89 Chloride USP, its been 'all systems go' to prep towards...

on 12/20/2019

2 min read